Inflammation: TREG cell control of autoimmune inflammation: a matter of timing?
Immunosuppression has been associated with viral reactivation in patients with chronic viral infections. a prospective study has concluded that it is safe to use anti-tumor-necrosis-factor agents in patients with chronic hepatitis B virus infection receiving antiviral prophylaxis. Is there sufficient evidence to back up this conclusion?